InfuSystem (NYSE:INFU – Get Free Report) and PolyPid (NASDAQ:PYPD – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.
Volatility & Risk
InfuSystem has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.
Insider & Institutional Ownership
71.1% of InfuSystem shares are owned by institutional investors. Comparatively, 26.5% of PolyPid shares are owned by institutional investors. 10.2% of InfuSystem shares are owned by company insiders. Comparatively, 24.7% of PolyPid shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| InfuSystem | 0 | 0 | 0 | 2 | 4.00 |
| PolyPid | 0 | 0 | 2 | 0 | 3.00 |
InfuSystem presently has a consensus target price of $13.00, indicating a potential upside of 60.49%. PolyPid has a consensus target price of $10.50, indicating a potential upside of 224.07%. Given PolyPid’s higher possible upside, analysts clearly believe PolyPid is more favorable than InfuSystem.
Valuation and Earnings
This table compares InfuSystem and PolyPid”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| InfuSystem | $132.78 million | 1.30 | $870,000.00 | $0.06 | 135.00 |
| PolyPid | N/A | N/A | -$23.86 million | ($7.81) | -0.41 |
InfuSystem has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares InfuSystem and PolyPid’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| InfuSystem | 1.12% | 2.78% | 1.41% |
| PolyPid | N/A | -1,219.71% | -134.48% |
Summary
InfuSystem beats PolyPid on 11 of the 14 factors compared between the two stocks.
About InfuSystem
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.
About PolyPid
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Receive News & Ratings for InfuSystem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InfuSystem and related companies with MarketBeat.com's FREE daily email newsletter.
